Cite Filings / SLN / 0001564590-22-026039
Feed Companies Filings Check
Sign in
SC 13D/A

Beneficial Ownership Report

Silence Therapeutics plc · Filed 2022-07-20 · Acc 0001564590-22-026039

Documents 1

  • SC 13D/A Beneficial Ownership Report , cik1846370-sc13da.htm

Around this filing

  • 2022-10-20 SC 13D/A Beneficial Ownership Report
  • 2022-07-20 SC 13D/A Beneficial Ownership Report
  • 2017-12-08 SC 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · TCG Crossover GP I, LLC 3.9%
  2. 2026-11-12 SCHEDULE 13G/A · Raymond Debbane 4.6%
  3. 2026-11-05 SCHEDULE 13G · FMR LLC 7.1%
  4. 2026-10-13 SCHEDULE 13G/A · Tetragon Financial Group Limited 5.3%
  5. 2026-10-13 SCHEDULE 13G · Tetragon Financial Group Limited 5.2%
  6. 2026-08-13 SCHEDULE 13G/A · Raymond Debbane 7.0%
  7. 2026-08-13 SCHEDULE 13D/A · Richard Griffiths 7.97%
  8. 2026-07-08 SCHEDULE 13D/A · Richard Griffiths 21.7%
  9. 2026-02-09 SCHEDULE 13G/A · Lombard Odier Asset Management (USA) Corp 4.2%
  10. 2025-06-25 SCHEDULE 13D/A · Richard Ian Griffiths 24.4%
  11. 2025-05-15 SCHEDULE 13G/A · Redmile Group, LLC 4.7%
  12. 2025-05-08 SCHEDULE 13D/A · Richard Ian Griffiths 23.2%
Loading cik1846370-sc13da.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…